<?xml version="1.0" encoding="UTF-8"?>
<p>All analyses are on an intention-to-treat basis. Categorical endpoints were compared using Mantel-Haenszel tests, giving Peto odds ratios and confidence intervals. Continuous/scale variables were analyzed by Wilcoxon rank sum tests and time-to-event outcomes using the log-rank test, with Kaplan-Meier survival curves. Odds/hazard ratios (OR/HR) &lt;1 indicate benefit for everolimus. All survival percentages refer to 5 years unless otherwise stated.</p>
